Infectious Diseases
The information provided is not intended to be a substitute for professional medical advice. A licensed healthcare professional should be consulted for diagnosis and treatment of any medical conditions.
Overview
The technologies in which we have special expertise - polysaccharide carrier protein conjugation, recombinant expression systems and cell culture - have the potential to open the door to a whole new generation of vaccines, to protect against both bacteria and viruses.
At our research center, in Austria, our scientists are working to apply these technologies both to new vaccines and also to improve the performance of Baxter's already marketed vaccines.
Baxter has developed a unique technology platform to manufacture Influenza vaccines at an industrial scale based on its proprietary serum protein free Vero cell technology, which can be used for the production of both seasonal and pandemic vaccines.
In March 2009, Baxter was the first to receive a cell culture-based H5N1pandemic mock up license from the European Medicines Agency (EMEA).
In October 2009, Baxter received the marketing authorization for the first cell culture-based, non-adjuvanted H1N1 pandemic influenza vaccine in the European Union.
Baxter continues to deliver vaccine to national public health authorities that have agreements with the company. Vaccines have already been received by a number of countries, including the UK, Ireland, New Zealand, Germany and Austria, for use in their national vaccination programs.
